UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019248
Receipt number R000022251
Scientific Title Evaluation of plasma Chromogranin A before and after treatment with various acid inhibitors
Date of disclosure of the study information 2015/10/14
Last modified on 2023/03/31 17:15:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of plasma Chromogranin A before and after treatment with various acid inhibitors

Acronym

Acid inhibitors and Chromogranin A

Scientific Title

Evaluation of plasma Chromogranin A before and after treatment with various acid inhibitors

Scientific Title:Acronym

Acid inhibitors and Chromogranin A

Region

Japan


Condition

Condition

acid-related gastrointestinal diseases

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the effect of acid inhibitors on ECL cell hyperplasia.

Basic objectives2

Others

Basic objectives -Others

To clarify the relationship between type of acid inhibitors and ECL cell hyperplasia.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Plasma Chromogranin A

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with acid-related gastrointestinal diseases, who were scheduled to treat with acid inhibitors for more than one month.
2) Patients with acid-related gastrointestinal diseases, who have been treated with acid inhibitors for more than 2 months.
3) Patients with written informed consent.

Key exclusion criteria

Patients who are not eligible for participation judged by a doctor.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Norihisa Ishimura

Organization

Shimane University Faculty of Medicine

Division name

Second department of Internal Medicine

Zip code


Address

89-1, Enya-cho, Izumo, Shimane

TEL

0853-20-2190

Email

ishimura@med.shimane-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Norihisa Ishimura

Organization

Shimane University Faculty of Medicine

Division name

Second department of Internal Medicine

Zip code


Address

89-1, Enya-cho, Izumo, Shimane

TEL

0853-20-2190

Homepage URL


Email

ishimura@med.shimane-u.ac.jp


Sponsor or person

Institute

Shimane University Faculty of Medicine

Institute

Department

Personal name



Funding Source

Organization

Shimane University Faculty of Medicine

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 10 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 09 Month 28 Day

Date of IRB

2015 Year 09 Month 28 Day

Anticipated trial start date

2015 Year 10 Month 14 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

A study before and after administration acid blocker (cohort study) and study during administration with acid blocker (cross-sectional study).
Enrollment of the patients: all patients who met the inclusion criteria after October 2015.


Management information

Registered date

2015 Year 10 Month 06 Day

Last modified on

2023 Year 03 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022251


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name